I haven’t yet to read the article you linked, but in principle any improvement to adverse-event reporting systems is a step forward. Better reporting, more transparency, and independent oversight are all things I strongly support. I’m absolutely in favour of rigorous, independent research into both the efficacy and the risks of any medication or treatment. That is not controversial - it’s how medicine is supposed to work. Pharmacovigilance systems exist precisely because no drug or medical intervention is risk-free, and ongoing monitoring is essential. That said, it’s also important to understand how these reporting systems actually function. Systems such as Vaccine Adverse Event Reporting System (VAERS) in the US or Yellow Card Scheme in the UK are designed as early-warning signal systems, not as proof that a reported event was caused by the drug or vaccine. As everyone (most) already know by now, anyone can submit a report - doctors, patients, or family members - and the reports are intentionally broad so that potential safety signals are not missed. That means the raw numbers are not evidence of causation until they are investigated and verified through proper epidemiological analysis. This is why large-scale follow-up studies, clinical data reviews, and independent regulatory monitoring exist through bodies like the World Health Organization, European Medicines Agency, and the U.S. Food and Drug Administration. These organisations analyse safety signals across millions - sometimes billions - of doses to determine whether there is a genuine causal relationship. Where I take issue is when fringe websites or advocacy groups selectively present raw reporting data without that context. That tends to create a misleading narrative that implies causation where there may only be correlation or coincidence. Ironically, that kind of distortion undermines legitimate discussion about real safety issues. To be clear - medical history shows that vigilance is necessary. Drugs such as Thalidomide or issues identified with certain medications years after approval are exactly why robust monitoring systems exist. But the solution is better science and better data, not selective interpretation of incomplete datasets. So if the update you’re referring to genuinely improves transparency or strengthens reporting accuracy, then that’s something I would welcome. I’ll read through the material to fully digest it when I have a spare hour.
